Journal of Crohn's and Colitis, 16, 3, pp. 389-397 Journal of Crohn's & Colitis Journal of Crohn's and Colitis, 16, 389-397 Chanchlani, N, Lin, S, Chee, D, Hamilton, B, Nice, R, Arkir, Z, Bewshea, C, Cipriano, B, Derikx, L A A P, Dunlop, A, Greathead, L, Griffiths, R L, Ibraheim, H, Kelleher, P, Kok, K B, Lees, C W, MacDonald, J, Sebastian, S, Smith, P J, McDonald, T J, Irving, P M, Powell, N, Kennedy, N A, Goodhand, J R & Ahmad, T 2022, ' Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses : Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients ', Journal of Crohn's & colitis, vol. 16, no. 3, pp. 389-397 . https://doi.org/10.1093/ecco-jcc/jjab153
Lin, S, Green, H D, Hendy, P, Heerasing, N M, Chanchlani, N, Hamilton, B, Walker, G J, Heap, G A, Hobart, J, Martin, R J, Coles, A J, Silverberg, M S, Irving, P M, Chung-Faye, G, Silber, E, Cummings, JR F, Lytvyak, E, Andersen, V, Wood, A R, Tyrrell, J, Beaumont, R N, Weedon, M N, Kennedy, N A, Spiers, A, Harrower, T, Goodhand, J R, Ahmad, T & PRED4 study group 2020, ' Clinical features and genetic risk of demyelination following anti-TNF treatment ', Journal of Crohn's and Colitis, vol. 14, no. 12, pp. 1653-1661 . https://doi.org/10.1093/ecco-jcc/jjaa104